EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial

3778 Effekte von Metformin auf Biomarker bei älteren Menschen mit Sarkopenie: Analyse der randomisierten kontrollierten MET-PREVENT-Studie

I Islam, J Wilson, A Clegg, H Hancock, C Martin-Ruiz, C McDonald, A A Sayer, C Steves, T von Zglinicki, M D Witham

Age and Ageing · 05.02.2026 · 55 (Supplement_1)

DOI: 10.1093/ageing/afaf368.097 ↗

Auf einen Blick

In der MET-PREVENT-Studie wurden bei älteren Menschen mit Sarkopenie nur schwache und uneinheitliche Zusammenhänge zwischen körperlicher Leistung und Biomarkern gesehen. Metformin senkte Insulin, änderte die meisten anderen Biomarker aber nicht signifikant.

Fragestellung

Welche Zusammenhänge bestehen zwischen körperlicher Leistungsfähigkeit und inflammatorischen/metabolischen Biomarkern bei älteren Menschen mit Sarkopenie, und wie wirkt Metformin auf dieses Biomarkerprofil?

Methode

Analyse von Proben aus der randomisierten kontrollierten MET-PREVENT-Studie mit Messungen zu Baseline und nach 4 Monaten; 500 mg Metformin 3x/Tag oder Placebo; Spearman- und Mann–Whitney-Tests.

Ergebnisse

72 Teilnehmende, mittleres Alter 80 Jahre. Höheres IL-6 zu Baseline korrelierte mit kürzerer 6-Minuten-Gehstrecke (r = −0,40; p = 0,008). Metformin senkte Insulin stärker als Placebo (-178 pg/ml [IQR -462, 180] vs. 147 pg/ml [IQR -89, 353]; p = 0,04).

Schlussfolgerung der Autor:innen

In dieser Studienpopulation waren die Zusammenhänge zwischen körperlicher Leistung und inflammatorischen/metabolischen Biomarkern schwach und inkonsistent; Metformin hatte auf die meisten gemessenen Biomarker keinen günstigen Effekt.

Kernaussagen

  • IL-6 zu Baseline: r = −0,40; p = 0,008 mit 6-Minuten-Gehstrecke
  • Metformin senkte Insulin stärker als Placebo
  • Die meisten anderen Biomarker änderten sich nicht signifikant

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Age and Ageing, online erschienen am 05.02.2026. Verfasst von I Islam und 9 weiteren Autor:innen.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic inflammation and metabolic dysfunction are posited to contribute to sarcopenia and physical frailty; both are targets for metformin therapy. We investigated correlations between physical performance measures and inflammatory and metabolic biomarkers in a group of older people with sarcopenia and frailty/prefrailty and investigated the effect of metformin treatment on this biomarker panel.

Methods

We analysed samples collected at baseline and follow-up (4 months) from the randomised controlled MET-PREVENT trial. MET-PREVENT recruited participants aged 65 and over with probable sarcopenia (EWGSOP2 guidelines) and 4 m walk speed <0.8 m/s. Participants received 500 mg metformin 3x/day or matching placebo for 4 months. Blood sampling and physical performance measures (handgrip strength, 4 m walk speed, six-minute walk distance, 5x sit to stand) were conducted at baseline and 4 months. Biomarkers were measured using ELISA and Luminex platforms for insulin, CRP, adiponectin, leptin, MCP-1, IL-1b, IL-6, IL-8, and TNF-a. Baseline correlations and correlations of changes between baseline and follow-up, were analysed using Spearman’s test; median change between baseline and follow-up in the metformin and placebo groups was compared using Mann–Whitney tests.

Results

Seventy-two participants were studied, mean age 80 years. Higher baseline IL-6 concentrations correlated with lower six-minute walk distance, (r = −0.40, p = 0.008); other correlations were non-significant. Increased IL-1B and decreased adiponectin between baseline and 4 months were correlated with worsening grip strength (r = −0.25, p = 0.04; r = 0.29, p = 0.016); increased TNF-a and decreased MCP-1 were correlated with worsening 5x sit-to-stand time (r = 0.38, p = 0.02; r = −0.32, p = 0.04). Metformin treatment reduced circulating insulin concentrations more than placebo (median change between baseline and 4 months: -178 pg/ml [IQR -462, 180] vs 147 pg/ml [IQR -89, 353]; between-group p = 0.04) but did not significantly change other biomarkers compared with placebo.

Conclusions

In this trial population, only weak and inconsistent correlations were seen between physical performance and inflammatory/metabolic biomarkers, and metformin did not beneficially affect most biomarkers measured.

Zitieren

APA

Islam, I., Wilson, J., Clegg, A., Hancock, H., Martin-Ruiz, C., McDonald, C., Sayer, A. A., Steves, C., Zglinicki, T. V., & Witham, M. D. (2026). 3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial. Age and Ageing, 55(Supplement_1). https://doi.org/10.1093/ageing/afaf368.097

Vancouver

Islam I, Wilson J, Clegg A, Hancock H, Martin-Ruiz C, McDonald C, et al. 3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial. Age and Ageing. 2026;55(Supplement_1). doi:10.1093/ageing/afaf368.097

BibTeX
@article{Islam2026,
  author = {Islam, I and Wilson, J and Clegg, A and Hancock, H and Martin-Ruiz, C and McDonald, C and Sayer, A A and Steves, C and Zglinicki, T von and Witham, M D},
  title = {3778 Effects of metformin on biomarkers in older people with sarcopenia: analysis from the MET-PREVENT randomised controlled trial},
  journal = {Age and Ageing},
  year = {2026},
  volume = {55},
  number = {Supplement_1},
  doi = {10.1093/ageing/afaf368.097}
}
Kostenlos starten →